Company Analysis
Sign in

X4 Pharmaceuticals, Inc. (XFOR)

Nasdaq: XFOR · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2010
Full chart Alerts Compare
Grade4.2
◀ Past 1.8● Present 3.4▶ Future 6.3
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

16 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to X4 Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
16
16 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and 2 in 2023
Applications published
33
8 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Organic fine chemistry4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
X4 Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
31 published
X4 Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
16 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 5, 202512,377,090Methods for treating neutropeniaPharmaceuticalsX4 Pharmaceuticals, Inc.
Apr 29, 202512,285,424Methods for treating neutropeniaPharmaceuticalsX4 Pharmaceuticals, Inc.
Oct 15, 202412,115,156Compositions of CXCR4 inhibitors and methods of preparation and usePharmaceuticalsX4 Pharmaceuticals, Inc.
Oct 10, 202311,780,837CXCR4 inhibitors and uses thereofOrganic fine chemistryX4 Pharmaceuticals, Inc.
Jun 13, 202311,672,793Compositions of CXCR4 inhibitors and methods of preparation and usePharmaceuticalsX4 Pharmaceuticals, Inc.
Jun 14, 202211,357,742Methods for treating cancerPharmaceuticalsX4 Pharmaceuticals, Inc.
May 24, 202211,337,969Methods for treating cancerPharmaceuticalsX4 Pharmaceuticals, Inc.
May 17, 202211,332,470CXCR4 inhibitors and uses thereofOrganic fine chemistryX4 Pharmaceuticals, Inc.
Apr 19, 202211,306,088CXCR4 inhibitors and uses thereofOrganic fine chemistryX4 Pharmaceuticals, Inc.
Jan 11, 202211,219,621Methods for treating immunodeficiency diseasePharmaceuticalsX4 Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0361307COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERSPharmaceuticalsX4 Pharmaceuticals, Inc.
Nov 6, 20252025/0339423METHODS FOR TREATING NEUTROPENIAPharmaceuticalsX4 Pharmaceuticals, Inc.
Oct 23, 20252025/0326753DUAL CXCR4-BTK INHIBITORSPharmaceuticalsX4 Pharmaceuticals, Inc.
Aug 7, 20252025/0248991METHODS FOR TREATING NEUTROPENIAPharmaceuticalsX4 Pharmaceuticals, Inc. · patent 12,377,090 granted from it
Jul 24, 20252025/0236604SYNTHESIS OF MAVORIXAFOR AND INTERMEDIATES THEREOFOrganic fine chemistryX4 Pharmaceuticals, Inc.
Jul 17, 20252025/0228843COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USEPharmaceuticalsX4 Pharmaceuticals, Inc.
May 15, 20252025/0152575METHODS FOR TREATING IMMUNODEFICIENCY DISEASEPharmaceuticalsX4 Pharmaceuticals, Inc.
Feb 6, 20252025/0041292METHODS FOR TREATING PRIMARY IMMUNODEFICIENCYPharmaceuticalsX4 Pharmaceuticals, Inc.
May 9, 20242024/0150350CXCR4 INHIBITORS AND USES THEREOFOrganic fine chemistryX4 Pharmaceuticals, Inc.
Feb 22, 20242024/0058322COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USEPharmaceuticalsX4 Pharmaceuticals, Inc. · patent 12,115,156 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton XFOR · research, not advice